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Abstract
There is debate about routine early invasive treatment compared with 
conservative treatment in non-ST-segment elevation acute coronary syn-
dromes (NSTE-ACS). Current guidelines recommend an early invasive 
approach in high-risk patients with acute coronary syndromes without 
ST-segment elevation. Over the past 10 years, there have been nine trials 
which randomized approximately 10,000 NSTE-ACS patients into an early 
invasive or conservative treatment strategy. In these trials, early invasive 
treatment was not associated with a reduction in mortality after 1 year of 
follow-up. However, early invasive treatment was associated with a border-
line statistically significant reduction in the composite endpoint of death 
or nonfatal myocardial infarction compared to conservative treatment. In 
addition, rehospitalization and refractory angina were less frequent in the 
early invasive strategy groups. Although the optimal timing of angiography 
and subsequent revascularization, if appropriate, remains controversial, we 
believe that for patients with NSTE-ACS, an early invasive strategy should 
be strongly considered during initial hospitalization in high-risk patients 
and in cases of medical therapy failure to reduce angina symptoms and 
rehospitalization, without increased risk of death or myocardial infarction. 
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Article info
Article history:
Received: May 24, 2007
Revised: June 4, 2007
Accepted: June 13, 2007
Keywords:
Conservative treatment 
 strategy
Early invasive strategy
Non-ST elevation acute
 coronary syndrome
*Corresponding author. Division of Cardiology, Department of Internal Medicine, Buddhist 
Dalin Tzu Chi General Hospital, 2, Min-Sheng Road, Dalin, Chiayi, Taiwan.
E-mail address: cllinmd@tzuchi.com.tw
© 2008 Buddhist Compassion Relief Tzu Chi Foundation
1. Introduction
Patients with acute coronary syndromes without 
ST-segment elevation are at risk of adverse car-
diac events [1]. Over the past decade, two distinct 
approaches have emerged in the management of 
patients with non-ST elevation acute coronary syn-
dromes (NSTE-ACS): (1) a routine early invasive strat-
egy that consists of routinely referring patients with 
NSTE-ACS for coronary angiography during the first 
days after admission (in the majority of patients, car-
diac catheterization is performed within 72 hours) 
and if necessary, revascularization as soon as pos-
sible thereafter; and (2) a conservative strategy (also 
referred to as a selective invasive or ischemic-guided 
strategy). In this strategy, patients are initially treated 
with pharmacological therapy, after which coronary 
angiography and revascularization, if appropriate, are 
20 TZU CHI MED J  March 2008  Vol 20  No 1
performed only for those with recurrent symptoms or 
objective evidence of inducible ischemia on nonin-
vasive tests. The American College of Cardiology–
American Heart Association and the European Society 
of Cardiology recommend an early invasive approach 
in high-risk patients with acute coronary syndromes 
without ST-segment elevation [2,3]. A number of 
randomized trials describe potential benefits of rou-
tine early invasive strategy for all patients with NSTE-
ACS regardless of their initial risk stratum. Is this an 
appropriate and rational approach? We undertook 
a review of the literature to examine this question.
2. Randomized trials
Over the past 10 years, there have been nine trials 
which randomized approximately 10,000 NSTE-ACS 
patients into an early invasive or conservative treat-
ment strategy [4–11] (Table 1).
In the Thrombolysis In Myocardial Infarction (TIMI-
IIIB) trial, the early invasive strategy was associated 
with a shorter hospital stay, fewer readmissions and 
less need for anti-angina medications, but there was 
no significant difference in cardiac events [4].
In the Veterans Affairs Non-Q-Wave Infarction 
Strategies in Hospital (VANQWISH) trial which in-
cluded people with non-Q-wave myocardial infarction 
(MI), patients randomized to early invasive treatment 
had significantly higher 1-year event rates compared 
to conservatively managed patients (22.1% vs. 14.2%; 
odds ratio [OR], 1.7; 95% confidence interval [CI], 
1.2–2.4). High perioperative mortality was observed 
in the invasive arm compared to the conservative 
treatment arm (11.6% vs. 3.4%; OR, 0.37; 95% CI, 
1.0–3.6) [6].
However, the TIMI-IIIB and VANQWISH trials were 
conducted in the pre-glycoprotein IIb/IIIa inhibitor 
therapy era and before the widespread use of stents.
In the Fragmin and Fast Revascularization dur-
ing Instability in Coronary Artery Disease (FRISC II) 
trial, 2457 patients with unstable coronary disease 
were randomized after 48 hours to an invasive or 
noninvasive approach [7]. All patients were treated 
with aspirin, intravenous nitroglycerin, beta-blockers, 
and low-molecular-weight heparin (dalteparin) for 
4–6 days until revascularization was performed in 
the invasive group, and for a similar duration in the 
noninvasive group. The invasive approach included 
catheterization followed by revascularization within 
7 days. Patients in the noninvasive arm had angi-
ography followed by revascularization if they had 
a marked positive exercise test, severe angina, or 
MI. At 6 months, the rate of death or MI was signifi-
cantly lower in the invasive treatment group (9.4% 
vs. 12.1%; risk ratio [RR], 0.78; 95% CI, 0.62–0.98; 
p = 0.031). There was a significant decrease in MI 
in the invasive group (7.8% vs. 10.1%; RR, 0.77; 
95% CI, 0.60–0.99; p = 0.045), while the difference 
in mortality was not significant. Invasive treatment 
provided the greatest advantages in older patients, 
in men, in those with chest pain at rest or longer 
durations of angina, and in patients with ST-segment
depression. The 2-year follow-up of the FRISC II cohort 
showed a consistent reduction and continued sepa-
ration of the event curves between the two strategies 
at 2 years. However, after enrolment, the prominent 
benefit between the two groups was most apparent 
within the first 6–12 months [12].
In the Treat Angina with Aggrastat and Determine 
Cost of Therapy with an Invasive or Conservative 
Strategy (TACTICS–TIMI 18) trial, 2220 patients with 
unstable angina or non-ST-elevation MI (NSTEMI) 
were randomized to an early invasive strategy (cathe-
terization within 4–48 hours and revascularization) or 
a conservative strategy [9]. All patients received aspi-
rin, beta-blockers, heparin, and tirofiban for 48–108 
hours. At 6 months, the primary endpoint (death, MI, 
rehospitalization for an acute coronary syndrome) 
was significantly lower in the invasive strategy group 
than the conservative strategy group (5.9% vs. 19.4%; 
OR, 0.78; 95% CI, 0.62–0.97; p = 0.025). The rate of 
death or non-fatal MI at 6 months was reduced in the 
invasive strategy group (7.3% vs. 9.5%; OR, 0.74; 
Table 1 — Nine randomized trials comparing early invasive with conservative strategy in NSTE-ACS patients
Study Year Follow-up
 Patients
   Conservative Invasive
TIMI IIIB 1994 6 wk 733 740
MATE 1998 21 mo 90 111
VANQWISH 1998 1 yr 458 462
FRISC II 2000 1 yr 1234 1222
TRUCS 2000 1 yr 72 76
TACTICS-TIMI 18 2001 6 mo 1106 1114
VINO 2002 6 mo 67 64
RITA 3 2002 1 yr 915 895
ICTUS 2005 1 yr 596 604
All    5271 5288
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95% CI, 0.54–1.0; p < 0.05). As in the FRISC II trial, 
the greatest benefit for the invasive strategy group 
was observed in patients with ST depression on 
the entry ECG, positive biomarkers, or ≥ 3 TIMI risk 
score. The clinical outcomes of patients with low risk 
did not differ between the invasive and conservative 
strategies.
The Randomized Intervention Trials of Unstable 
Angina (RITA 3) trial [11] showed that an interventional 
strategy was preferable to a conservative strategy in 
1810 patients with NSTE-ACS (mean age, 62 years; 
38% women). The difference was mainly due to a 
halving of refractory angina in the intervention group. 
Death or MI was similar in both treatment groups at 
1 year (7.6% vs. 8.3%; RR, 0.91; 95% CI, 0.67–1.25; 
p = 0.58).
In the Invasive versus Conservative Treatment in 
Unstable Coronary Syndromes (ICTUS) trial, 1201 
NSTE-ACS patients with cardiac troponin T levels
≥ 0.03 µg per liter at admission were randomly 
assigned to an early invasive strategy (coronary angi-
ography and subsequent revascularization within 
24–48 hours) or to a selective invasive strategy [13]. 
Patients received aspirin daily, enoxaparin for 48 
hours, and abciximab at the time of percutaneous 
coronary intervention. The protocol recommended 
intensive lipid-lowering therapy and the use of clopi-
dogrel. Nonfatal MI was significantly increased in the 
early invasive group during the 1-year follow-up (15% 
vs. 10%; OR, 1.5; 95% CI, 1.1–2.0; p = 0.005), but 
most events were procedure-related. The mortality 
rate was the same (2.5%). Rehospitalization was less 
frequent in the early invasive group (7.4% vs. 10.9%; 
OR, 0.68; 95% CI, 0.47–0.90; p = 0.04).
In the FRISC II, TACTICS–TIMI 18, and RITA 3 trials, 
an early invasive strategy improved survival without 
recurrence of MI, readmission and urgent revascu-
larization for severe angina (Table 2).
A meta-analysis of the FRISC II, TRUCS, TACTICS–
TIMI 18, VINO, and RITA 3 trials revealed a 28% 
reduction (and a 2.5% absolute reduction) in the 
composite endpoint of death or nonfatal MI in the 
early invasive strategy groups (7% vs. 9.5%; OR, 0.72; 
95% CI, 0.6–0.86).
When all trials were considered, early invasive 
treatments were not associated with a mortality reduc-
tion after 1 year of follow-up (Table 3; Fig. 1). Early 
invasive treatment was associated with a borderline 
significant 12% relative reduction (and 1.1% abso-
lute reduction) in the composite endpoint of death 
or nonfatal MI during the 1-year follow-up (8.7% vs. 
9.8%; OR, 0.88; 95% CI, 0.77–1.0) (Table 3; Fig. 2).
In these trials, there was a high rate of crossover 
of patients from the conservative treatment group to 
the early revascularization group. Revascularization 
rates were high in the two treatment strategies as 
Table 2 — Outcomes of three randomized trials comparing early invasive (Inv) with conservative (Cons) strategy in 
NSTE-ACS patients
Outcomes
  Death, MI, or severe      
 angina leading to
  readmission/ Death or  Death  Spontaneous Procedure-related
 revascularization (%) MI (%) (%) MI (%) MI (%)6–12 mo
 Cons Inv Cons Inv Cons Inv Cons Inv Cons Inv
FRISC II 42.2 13.2 14.1 10.4 3.9 2.2 11.3 4.2 2.1 5.4
TACTICS 19.4 15.9 9.5 7.3 3.5 3.3 – – – –
RITA 3 14.5 9.6 8.3 7.6 3.9 4.6 5.7 3.3 0.4 1.7
Table 3 — Outcomes during 1-year follow-up in randomized trials of invasive (Inv) versus conservative (Cons) treatment 
in NSTE-ACS patients
Study
 Death (%) Death or nonfatal MI (%)
 Cons Inv Cons Inv
TIMI IIIB 18 (2.5)  18 (2.4) 60 (8.2)  56 (7.6)
MATE 9 (10)  12 (10.8) 11 (12.2)  15 (13.5)
VANQWISH 37 (8.1)  61 (13.2) 65 (14.2)  102 (22.1)
FRISC II 48 (3.9)  27 (2.2) 143 (11.6)  105 (8.6)
TRUCS 9 (12.5)  3 (3.9) 12 (16.7)  6 (7.9)
TACTICS TIMI-18 39 (3.5)  37 (3.3) 76 (6.9)  53 (4.8)
VINO 9 (13.4)  2 (3.1) 15 (22.4)  4 (6.3)
RITA 3 36 (3.9)  41 (4.6) 76 (8.3)  68 (7.6)
ICTUS 15 (2.5)  15 (2.5) NR  NR
All 220 (4.2)  216 (4.1) 458 (9.8)  409 (8.7)
NR = not reported.
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follows: in TIMI-IIIB, 64% in the early invasive 
group and 58% in the conservative group at 1 year; 
VANQWISH, 44% vs. 33% at 23 months; FRISC II, 
71% vs. 9% at 10 days and 77% vs. 37% at 6 months; 
TACTICS-TIMI 18, 61% vs. 44% at 6 months; RITA 3, 
44% vs. 10% during the index admission and 57% 
vs. 28% within 1 year; and ICTUS, 76% vs. 40% dur-
ing the initial hospitalization and 79% vs. 54% within 
1 year [4,6,7,9,11,13]. The high crossover rate may 
underestimate the benefits of an invasive approach.
3. Timing of revascularization
In most trials, patients randomized to the invasive 
approach underwent cardiac catheterization within 
72 hours and, if necessary, revascularization as soon 
as possible.
Early revascularization is associated with a higher 
risk of early death and MI because of procedure-
related events. The TIMI-IIIB and VANQWISH trials 
showed an approximately 60% excess MI rate within 
the first 2 weeks with an early invasive approach 
in NSTE-ACS patients [4,6]. However, the TIMI-IIIB 
and VANQWISH trials were conducted in the pre-
glycoprotein IIb/IIIa inhibitor therapy era, and before 
the widespread use of stents (Table 4). This rise in 
early in-hospital risk is compensated for by a lower 
risk of spontaneous events after revascularization, 
as in the FRISC II and RITA 3 trials [7,11]. In TACTICS-
TIMI 18, the risk of procedure-related MI could have 
been reduced by routine glycoprotein IIb/IIIa inhibi-
tion, suggesting that glycoprotein IIb/IIIa inhibitor 
administration mitigates the adverse consequences 
of distal embolization and incomplete platelet inhibi-
tion associated with early intervention [9].
In the VANQWISH and GUSTO IV-ACS trials, an in -
crease in mortality was found in patients with early 
coronary artery bypass graft (CABG) surgery [6,14]. 
In the FRISC II and TACTICS-TIMI 18 trials, the out-
come was comparable between patients undergoing 
CABG and percutaneous coronary intervention (PCI) 
[7,9].
Possibly, when indicated, PCI should be per-
formed as soon as possible after admission for 
ACS and only patients who might gain from early 
Invasive
better
Conservative
better
Odds ratio (95% CI) for death or MI
210
ALL TRIALS
Odds ratio, 0.88
95% CI, 0.76–1.0
ICTUS (2005)
RITA-3 (2002)
VINO (2002)
TACTICS (2001)
TRUCS (2000)
FRISC-II (2000)
VANQWISH (1998)
MATE (1998)
TIMB-III (1994)
Fig. 2 — Odds ratio of the composite endpoint of death 
or nonfatal myocardial infarction (MI) in nine randomized 
trials comparing invasive with selective invasive manage-
ment of non-ST-elevation acute coronary syndromes. CI = 
confidence interval.
Invasive
better
Conservative
better
Odds ratio (95% CI) for death
210
ALL TRIALS
Odds ratio, 0.98
95% CI, 0.8–1.19
ICTUS (2005)
RITA-3 (2002)
VINO (2002)
TACTICS (2001)
TRUCS (2000)
FRISC-II (2000)
VANQWISH (1998)
MATE (1998)
TIMB-III (1994)
Fig. 1 — Odds ratio of mortality in nine randomized tri-
als comparing invasive with selective invasive manage-
ment of non-ST-elevation acute coronary syndromes. CI = 
confidence interval.
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revascularization should be referred for CABG. 
However, the appropriate timing of coronary angiog-
raphy and revascularization remains controversial.
4. Subgroups of patients
Risk stratification remains an important part of opti-
mal clinical decision making today because NSTE-
ACS is heterogeneous, representing a spectrum of risk 
ranging from low to high.
The FRISC II and TACTICS-TIMI 18 trials did not 
demonstrate clear superiority for patients who were 
biomarker-negative and those without ST-segment 
depression [7,9].
In the FRISC II and RITA 3 trials, there were sig-
nificant interactions with sex, with significant reduc-
tions of the composite of death and MI in men but 
trends to hazards in women [7,11]. But in the ICTUS 
trial, the relative risks were not different between 
genders [13].
Increasing age is an important risk factor for ad-
verse outcomes in NSTE-ACS patients. Elderly patients 
are often managed conservatively. A subgroup analy-
sis of patients in the FRISC II and TACTICS-TIMI 18 
trials showed that an early invasive strategy can sig-
nificantly improve outcomes in elderly patients [7,9].
Diabetes is an independent predictor of mortal-
ity in NSTE-ACS patients. However, in most studies, 
coronary revascularization in patients with diabetes 
and NSTE-ACS was as effective as in patients without 
diabetes.
5. Conclusion
When all trials were considered together, early inva-
sive treatment was not associated with a mortality 
reduction after the 1-year follow-up. However, it was 
associated with a statistically significant reduction in 
the composite endpoint of death or nonfatal MI com-
pared to conservative treatment. In addition, rehos-
pitalization and refractory angina were less frequent 
with an early invasive strategy.
Thus, for patients with NSTE-ACS, an early invasive 
strategy should be strongly considered during initial 
hospitalization, especially in high-risk patients, such 
as older patients, men, and patients with diabetes, 
ST-segment depression, and intractable angina, with 
the aim of reducing angina symptoms and rehospitali-
zation,without increased risk of death or MI.
The optimal timing of coronary angiography and 
subsequent revascularization, if appropriate, remains 
controversial, but possibly, PCI should be performed 
as soon as possible after admission, whereas CABG 
can be deferred until the patient is more stable.
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